Clinical usefulness of bisphosphonates in oncology: Treatment of bone metastases, antitumoral activity and effect on bone resorption markers

A. Verì, M. R. D'Andrea, P. Bonginelli, Giampietro Gasparini

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The present article overviews the role of bisphosphonates for the treatment and prevention of bone metastases and their antiangiogenic effects and antitumoral activity. The skeleton is a frequent and clinically relevant site of metastasis in cancer patients. The major events related to bone metastases include bone pain, bone loss, hypercalcemia, spinal cord compression, and fractures. On the basis of their radiographic features, bone metastases are classified as osteoblastic, osteoclastic, or mixed. The primary goals of treatment of bone metastases are reduction of the risk of pathological fractures and other skeletal-related events, and pain control. Bisphosphonates are used to prevent pathological fractures by inhibition of osteoclasts. Recent studies suggest that bisphosphonates have some direct antitumoral activity, mainly mediated through the blockade of angiogenic pathways. Further clinical studies are needed to determine the optimal treatment duration, timing and schedule of bisphosphonates, assess their role as adjuvant therapy for the prevention of bone metastases, and establish their antiangiogenic activity in association with standard cytotoxic and hormonal drugs for treatment of patients with advanced disease.

Original languageEnglish
Pages (from-to)24-33
Number of pages10
JournalInternational Journal of Biological Markers
Volume22
Issue number1
Publication statusPublished - Jan 2007

Fingerprint

Oncology
Diphosphonates
Bone Resorption
Bone
Neoplasm Metastasis
Bone and Bones
Spontaneous Fractures
Therapeutics
Spinal Fractures
Compression Fractures
Pain
Spinal Cord Compression
Hypercalcemia
Osteoclasts
Risk Reduction Behavior
Skeleton
Appointments and Schedules
Compaction
Association reactions
Pharmaceutical Preparations

Keywords

  • Bisphosphonates
  • Bone metastases
  • Cancer
  • Quality of life
  • Zoledronic acid

ASJC Scopus subject areas

  • Immunology
  • Biochemistry

Cite this

Clinical usefulness of bisphosphonates in oncology : Treatment of bone metastases, antitumoral activity and effect on bone resorption markers. / Verì, A.; D'Andrea, M. R.; Bonginelli, P.; Gasparini, Giampietro.

In: International Journal of Biological Markers, Vol. 22, No. 1, 01.2007, p. 24-33.

Research output: Contribution to journalArticle

@article{b250f0c83a0c4f6bb335a7ce7e683191,
title = "Clinical usefulness of bisphosphonates in oncology: Treatment of bone metastases, antitumoral activity and effect on bone resorption markers",
abstract = "The present article overviews the role of bisphosphonates for the treatment and prevention of bone metastases and their antiangiogenic effects and antitumoral activity. The skeleton is a frequent and clinically relevant site of metastasis in cancer patients. The major events related to bone metastases include bone pain, bone loss, hypercalcemia, spinal cord compression, and fractures. On the basis of their radiographic features, bone metastases are classified as osteoblastic, osteoclastic, or mixed. The primary goals of treatment of bone metastases are reduction of the risk of pathological fractures and other skeletal-related events, and pain control. Bisphosphonates are used to prevent pathological fractures by inhibition of osteoclasts. Recent studies suggest that bisphosphonates have some direct antitumoral activity, mainly mediated through the blockade of angiogenic pathways. Further clinical studies are needed to determine the optimal treatment duration, timing and schedule of bisphosphonates, assess their role as adjuvant therapy for the prevention of bone metastases, and establish their antiangiogenic activity in association with standard cytotoxic and hormonal drugs for treatment of patients with advanced disease.",
keywords = "Bisphosphonates, Bone metastases, Cancer, Quality of life, Zoledronic acid",
author = "A. Ver{\`i} and D'Andrea, {M. R.} and P. Bonginelli and Giampietro Gasparini",
year = "2007",
month = "1",
language = "English",
volume = "22",
pages = "24--33",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "1",

}

TY - JOUR

T1 - Clinical usefulness of bisphosphonates in oncology

T2 - Treatment of bone metastases, antitumoral activity and effect on bone resorption markers

AU - Verì, A.

AU - D'Andrea, M. R.

AU - Bonginelli, P.

AU - Gasparini, Giampietro

PY - 2007/1

Y1 - 2007/1

N2 - The present article overviews the role of bisphosphonates for the treatment and prevention of bone metastases and their antiangiogenic effects and antitumoral activity. The skeleton is a frequent and clinically relevant site of metastasis in cancer patients. The major events related to bone metastases include bone pain, bone loss, hypercalcemia, spinal cord compression, and fractures. On the basis of their radiographic features, bone metastases are classified as osteoblastic, osteoclastic, or mixed. The primary goals of treatment of bone metastases are reduction of the risk of pathological fractures and other skeletal-related events, and pain control. Bisphosphonates are used to prevent pathological fractures by inhibition of osteoclasts. Recent studies suggest that bisphosphonates have some direct antitumoral activity, mainly mediated through the blockade of angiogenic pathways. Further clinical studies are needed to determine the optimal treatment duration, timing and schedule of bisphosphonates, assess their role as adjuvant therapy for the prevention of bone metastases, and establish their antiangiogenic activity in association with standard cytotoxic and hormonal drugs for treatment of patients with advanced disease.

AB - The present article overviews the role of bisphosphonates for the treatment and prevention of bone metastases and their antiangiogenic effects and antitumoral activity. The skeleton is a frequent and clinically relevant site of metastasis in cancer patients. The major events related to bone metastases include bone pain, bone loss, hypercalcemia, spinal cord compression, and fractures. On the basis of their radiographic features, bone metastases are classified as osteoblastic, osteoclastic, or mixed. The primary goals of treatment of bone metastases are reduction of the risk of pathological fractures and other skeletal-related events, and pain control. Bisphosphonates are used to prevent pathological fractures by inhibition of osteoclasts. Recent studies suggest that bisphosphonates have some direct antitumoral activity, mainly mediated through the blockade of angiogenic pathways. Further clinical studies are needed to determine the optimal treatment duration, timing and schedule of bisphosphonates, assess their role as adjuvant therapy for the prevention of bone metastases, and establish their antiangiogenic activity in association with standard cytotoxic and hormonal drugs for treatment of patients with advanced disease.

KW - Bisphosphonates

KW - Bone metastases

KW - Cancer

KW - Quality of life

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=34248402338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248402338&partnerID=8YFLogxK

M3 - Article

C2 - 17393358

AN - SCOPUS:34248402338

VL - 22

SP - 24

EP - 33

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 1

ER -